Daiwa Securities Group Inc. Sells 1,157 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

Daiwa Securities Group Inc. reduced its holdings in BeiGene, Ltd. (NASDAQ:BGNE) by 87.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 172 shares of the company’s stock after selling 1,157 shares during the period. Daiwa Securities Group Inc.’s holdings in BeiGene were worth $31,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Toronto Dominion Bank grew its stake in shares of BeiGene by 166.4% in the 3rd quarter. Toronto Dominion Bank now owns 333 shares of the company’s stock worth $60,000 after buying an additional 208 shares in the last quarter. Knights of Columbus Asset Advisors LLC boosted its stake in shares of BeiGene by 20.5% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company’s stock worth $80,000 after purchasing an additional 76 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of BeiGene by 123.9% during the 3rd quarter. PNC Financial Services Group Inc. now owns 732 shares of the company’s stock worth $132,000 after purchasing an additional 405 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of BeiGene by 98.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,078 shares of the company’s stock worth $194,000 after purchasing an additional 536 shares during the period. Finally, Clear Harbor Asset Management LLC purchased a new position in shares of BeiGene during the 4th quarter worth about $208,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO John Oyler sold 37,668 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $164.02, for a total value of $6,178,305.36. Following the completion of the sale, the chief executive officer now directly owns 12,332 shares in the company, valued at $2,022,694.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CFO Julia Aijun Wang sold 397 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $167.08, for a total value of $66,330.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John Oyler sold 37,668 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $164.02, for a total transaction of $6,178,305.36. Following the completion of the sale, the chief executive officer now owns 12,332 shares of the company’s stock, valued at $2,022,694.64. The disclosure for this sale can be found here. Insiders have sold 64,781 shares of company stock valued at $10,222,381 in the last ninety days. Insiders own 7.40% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. TD Cowen lifted their price target on shares of BeiGene from $235.00 to $236.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Bank of America lowered their price objective on shares of BeiGene from $179.30 to $164.30 and set a “neutral” rating for the company in a research report on Monday, April 8th. Sanford C. Bernstein lowered their price objective on shares of BeiGene from $196.00 to $161.00 and set a “market perform” rating for the company in a research report on Wednesday, March 27th. JPMorgan Chase & Co. boosted their price objective on shares of BeiGene from $184.00 to $186.00 and gave the company an “overweight” rating in a research report on Tuesday, March 19th. Finally, Guggenheim lowered their price objective on shares of BeiGene from $350.00 to $345.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, BeiGene currently has an average rating of “Moderate Buy” and an average price target of $250.13.

BeiGene Stock Up 3.4 %

BGNE stock opened at $153.58 on Monday. The firm’s fifty day simple moving average is $154.84 and its 200-day simple moving average is $167.09. The company has a market capitalization of $14.69 billion, a P/E ratio of -18.07 and a beta of 0.61. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.32 and a quick ratio of 2.09. BeiGene, Ltd. has a 12 month low of $126.97 and a 12 month high of $266.67.

BeiGene (NASDAQ:BGNE) last released its quarterly earnings data on Monday, February 26th. The company reported ($3.53) EPS for the quarter, beating the consensus estimate of ($3.61) by $0.08. The business had revenue of $634.40 million for the quarter, compared to the consensus estimate of $632.52 million. BeiGene had a negative net margin of 35.86% and a negative return on equity of 23.12%. The business’s revenue for the quarter was up 66.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($4.29) EPS. As a group, equities research analysts forecast that BeiGene, Ltd. will post -8.93 earnings per share for the current year.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.